United States Patent 8,883,206: Ivacaftor Formulation Scope, Patent Claims, and Generic-Entry Risk
U.S. Patent No. 8,883,206 protects a specific oral pharmaceutical composition containing amorphous ivacaftor in an HPMCAS/SLS solid dispersion, combined with mannitol, lactose, sucralose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The patent is formulation-specific rather than a broad compound patent. Its strongest coverage is directed to 50 mg and 75 mg unit doses delivered as approximately 2 mm mini-tablets, including 26-mini-tablet and 39-mini-tablet configurations.
The patent does not broadly cover every ivacaftor product, every amorphous ivacaftor formulation, or every pediatric dosage form. Infringement generally requires practicing the claimed excipient composition, solid-dispersion ratios, amorphous active form, and, for dependent claims, the specified dose and mini-tablet architecture.
What drug does U.S. Patent 8,883,206 protect?
The active pharmaceutical ingredient is ivacaftor, the CFTR potentiator marketed by Vertex Pharmaceuticals as Kalydeco. The chemical name recited in the claims is:
N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide.
Ivacaftor increases the open probability of defective CFTR chloride channels. Kalydeco is approved for cystic fibrosis patients with specified responsive CFTR mutations and is marketed in tablet, granule, and combination-product presentations. The formulation claimed in Patent 8,883,206 is aligned with an oral solid dosage design intended to improve ivacaftor dissolution and support flexible pediatric administration.
What is the scope of independent claim 1?
Claim 1 is a composition claim using the closed transitional phrase “consisting of.” Its required architecture is:
| Required element |
Claimed amount |
| Solid dispersion |
About 35 wt% of total composition |
| Amorphous or substantially amorphous ivacaftor in dispersion |
About 80 wt% of dispersion |
| HPMCAS in dispersion |
About 19.5 wt% of dispersion |
| SLS in dispersion |
About 0.5 wt% of dispersion |
| Mannitol |
About 13.5 wt% |
| Lactose |
About 41 wt% |
| Sucralose |
About 2 wt% |
| Croscarmellose sodium |
About 6 wt% |
| Colloidal silicon dioxide |
About 1 wt% |
| Magnesium stearate |
About 1.5 wt% |
The percentages in the external composition total approximately 100%, while the solid-dispersion components total 100% of the dispersion. The claim therefore describes a highly specific formulation rather than a functional genus.
How does the “consisting of” language affect infringement?
“Consisting of” normally excludes additional material components that materially alter the claimed composition. A competing product containing a different sweetener, binder, lubricant, surfactant, or disintegrant may avoid literal infringement if the additional ingredient is part of the pharmaceutical composition.
The analysis becomes more complex where:
- an excipient is present only as a processing aid;
- a listed ingredient is replaced with a chemically equivalent material;
- the product contains trace impurities;
- the formulation is manufactured with an unlisted coating or capsule component;
- the accused product uses the same ingredients but falls outside the stated weight ranges.
The “about” modifiers provide numerical flexibility, but they do not eliminate the requirement to prove that the accused formulation falls within a reasonable range around each recited percentage. The patent does not state in the provided claims how much variation “about” permits.
What does the solid-dispersion limitation require?
The formulation must contain ivacaftor in a substantially amorphous or amorphous state. The active must be present in a solid dispersion with:
- approximately 80 wt% ivacaftor;
- approximately 19.5 wt% HPMCAS; and
- approximately 0.5 wt% sodium lauryl sulfate.
HPMCAS is hydroxypropyl methylcellulose acetate succinate. It is a polymer commonly used to improve dissolution and inhibit precipitation of poorly water-soluble compounds. SLS is sodium lauryl sulfate and functions as a surfactant.
A crystalline ivacaftor formulation would not satisfy the express amorphous-active limitation. A solid dispersion using a different polymer, such as PVP, PVP-VA, HPMC, or a different grade of cellulose derivative, would present a substantial literal-infringement defense unless the formulation also met the claimed HPMCAS requirement.
The claim is also sensitive to manufacturing and analytical proof. Relevant evidence may include powder X-ray diffraction, differential scanning calorimetry, solid-state nuclear magnetic resonance, Raman spectroscopy, microscopy, and manufacturing batch records.
What dosage forms and strengths are covered by claims 2 through 10?
Claims 2 through 10 narrow claim 1 by adding unit-dose and mini-tablet limitations.
| Claim |
Added limitation |
| 2 |
Unit dose contains one or more granules, pellets, particles, or mini-tablets and 1-100 mg ivacaftor |
| 3 |
Approximately 50 mg ivacaftor |
| 4 |
Approximately 75 mg ivacaftor |
| 5 |
Approximately 25-40 mini-tablets |
| 6 |
Approximately 35% solid dispersion and approximately 26 mini-tablets |
| 7 |
Claim 6 plus approximately 50 mg ivacaftor |
| 8 |
Approximately 35% solid dispersion and approximately 39 mini-tablets |
| 9 |
Claim 8 plus approximately 75 mg ivacaftor |
| 10 |
Claim 5 plus approximately 2 mm longest dimension or diameter and specified shapes |
Claims 7 and 9 are commercially significant because they map closely onto 50 mg and 75 mg pediatric or flexible-dose presentations. Claim 10 adds physical dimensions and shapes, including cylinder-like, oval-like, cone-like, sphere-like, ellipsis-like, polygon-like, or combinations of those forms.
The claim language creates an important distinction between:
- a composition that contains the required formulation but is not divided into mini-tablets;
- a composition supplied as granules or pellets;
- a 26-mini-tablet unit dose; and
- a 39-mini-tablet unit dose.
A product may fall within claim 1 while avoiding claims 5 through 10 if it uses a different dosage form. Conversely, a product using 26 or 39 mini-tablets must still satisfy every limitation inherited from claim 1.
How strong is the patent estate for ivacaftor?
Ivacaftor has multiple patent layers. The formulation patent should be evaluated separately from the basic compound and CFTR-use patents.
| Patent layer |
Principal subject matter |
Commercial relevance |
| Compound patents |
Ivacaftor and related quinolinone compounds |
Broadest chemical protection |
| CFTR use patents |
Treatment of cystic fibrosis and CFTR mutations |
Method-of-use protection |
| Solid-state patents |
Amorphous or crystalline ivacaftor forms |
Protects physical form and stability |
| Formulation patents |
Solid dispersions, excipients, tablets, granules, mini-tablets |
Protects product design |
| Combination patents |
Ivacaftor with CFTR correctors such as lumacaftor, tezacaftor, or elexacaftor |
Protects combination products |
| Manufacturing patents |
Preparation, granulation, dispersion, and dosage-form processes |
Can create process and supply-chain barriers |
The foundational U.S. ivacaftor compound patent is U.S. Patent No. 7,495,103, assigned to Vertex Pharmaceuticals. Its nominal patent term has been associated with expiration in late 2026, subject to patent-term adjustment or extension treatment. U.S. Patent No. 8,883,206 is a later formulation patent with a nominal term extending to approximately June 2029 based on its priority framework and ordinary 20-year term calculation. The precise enforceable term depends on the USPTO term calculation and any applicable patent-term adjustment.
The estate is stronger as a portfolio than as a single patent. A generic applicant that designs around Patent 8,883,206 may still face compound, solid-state, method-of-use, or combination patents.
What is the Orange Book status of U.S. Patent 8,883,206?
FDA Orange Book listings identify patents submitted by NDA sponsors for approved drug products. Kalydeco has been listed under NDA 203188, with patents covering the active ingredient, formulations, and approved uses. Patent 8,883,206 has been associated with ivacaftor formulation protection and is relevant to Kalydeco’s oral solid dosage products.
Orange Book relevance depends on the specific dosage form and strength listed against the patent. A patent directed to mini-tablets or a particular formulation may be more relevant to a generic seeking approval for granules or tablets than to every possible ivacaftor product.
An Orange Book listing does not establish validity or infringement. It creates a regulatory patent-notification consequence for an ANDA applicant that seeks approval before the listed patent’s expiration.
When does ivacaftor lose exclusivity?
Ivacaftor exclusivity has several dates rather than one universal endpoint.
| Protection |
Approximate timing |
Effect |
| New chemical entity exclusivity |
Expired |
Prevented certain ANDA submissions for the statutory period |
| Foundational compound patent |
Late 2026 nominally |
Broad ivacaftor protection |
| Formulation Patent 8,883,206 |
Approximately June 2029 nominally |
Protects the claimed solid-dispersion and mini-tablet composition |
| Combination-product patents |
Varies by patent and product |
Relevant to Orkambi, Symdeko, and Trikafta components |
| Pediatric exclusivity |
Six months where granted |
Adds to qualifying patent or exclusivity periods |
The practical generic-entry date depends on which patents are listed for the target NDA, whether an ANDA applicant files a Paragraph IV certification, whether litigation triggers a 30-month stay, and whether the parties settle.
What Paragraph IV challenges could target this patent?
An ANDA applicant could challenge Patent 8,883,206 by certifying that the patent is invalid, unenforceable, or not infringed. The most plausible design-around and validity positions are formulation-specific.
Non-infringement positions
A challenger could argue that its product:
- uses crystalline rather than amorphous ivacaftor;
- uses a polymer other than HPMCAS;
- omits SLS or uses a materially different SLS concentration;
- does not contain approximately 35 wt% solid dispersion;
- substitutes lactose, mannitol, sucralose, or another excipient;
- uses a capsule, conventional tablet, or powder rather than the claimed mini-tablet arrangement;
- contains a different number or size of mini-tablets;
- falls outside the combined weight-percentage limitations.
The closed claim format makes ingredient substitution particularly useful. A formulation that replaces one listed excipient may avoid literal infringement, although the doctrine of equivalents could remain relevant.
Validity positions
Potential validity attacks could focus on:
- anticipation by earlier ivacaftor solid-dispersion disclosures;
- obviousness based on known amorphous-drug formulations and HPMCAS systems;
- indefiniteness of “about,” “substantially amorphous,” “cylinder-like,” and related shape terms;
- written-description support for the precise percentage combinations;
- enablement of the full scope of the composition ranges;
- lack of clear boundaries for the 2 mm dimension and mini-tablet shapes.
The patent’s defense would likely rely on the specific excipient combination, dissolution or stability data, manufacturing reproducibility, and evidence that the claimed composition produced an unexpected formulation result.
Which companies are challenging ivacaftor patent protection?
Public generic activity for ivacaftor should be assessed by ANDA applicant, target NDA, dosage form, and patent certification. Small-molecule generic applicants, rather than biosimilar sponsors, are the relevant challengers.
The key regulatory distinction is:
- an ANDA applicant may seek approval for an ivacaftor tablet or granule product;
- a Paragraph IV certification can trigger patent litigation;
- a Section VIII statement may permit approval for non-patented uses;
- a formulation patent may be avoided through a product that does not use the claimed composition.
A biosimilar pathway under the Biologics Price Competition and Innovation Act does not apply because ivacaftor is a chemically synthesized small molecule, not a biologic.
What patent litigation affects U.S. Patent 8,883,206?
Patent litigation must be linked to a particular ANDA, NDA, and asserted patent. The supplied claim text does not establish a litigation history for Patent 8,883,206. A litigation search should distinguish:
- cases involving the foundational ivacaftor compound patents;
- cases involving Kalydeco formulation patents;
- cases involving combination products;
- declaratory-judgment actions;
- patent settlements that restrict launch timing without producing a final validity decision.
A complaint or settlement involving another ivacaftor patent does not establish that Patent 8,883,206 was asserted, adjudicated, or waived.
What manufacturing and IP barriers does the patent create?
The patent creates several practical barriers beyond the ingredient list.
First, the manufacturer must control the amorphous solid-dispersion process. Spray drying, solvent removal, polymer selection, residual-solvent control, and scale-up can affect ivacaftor crystallization and dissolution.
Second, the final unit dose must maintain the claimed composition after granulation, compression, lubrication, and packaging. The 26-mini-tablet and 39-mini-tablet configurations add equipment and content-uniformity requirements.
Third, an ANDA sponsor may need to demonstrate bioequivalence against the reference product while avoiding the claimed formulation. A technically successful design-around may still require substantial development work if a different formulation changes dissolution, food effect, stability, or dose uniformity.
The patent therefore has more commercial value for products that closely replicate Kalydeco’s pediatric or multiparticulate presentation than for a conventional adult tablet with materially different excipients.
How does Patent 8,883,206 compare with the foundational ivacaftor patent?
| Issue |
Foundational compound patent |
U.S. 8,883,206 |
| Protected subject matter |
Ivacaftor chemical entity and related compounds |
Specific ivacaftor formulation |
| Breadth |
Broad chemical scope |
Narrow composition scope |
| Design-around difficulty |
High before expiration |
Moderate to high |
| Required amorphous form |
No, depending on claim |
Yes |
| Required excipients |
Generally no |
Yes |
| Mini-tablet limitations |
Generally no |
Yes, in dependent claims |
| Generic relevance |
Any ivacaftor product |
Products using the claimed formulation |
| Nominal expiration |
Approximately late 2026 |
Approximately June 2029 |
| Primary risk |
Product-level exclusion |
Formulation-specific infringement |
The formulation patent can extend meaningful protection beyond the compound patent, but it is easier to design around. Its commercial strength depends on whether a generic can achieve acceptable bioequivalence with a different excipient system or dosage form.
Key Takeaways
- U.S. Patent 8,883,206 is a formulation patent for amorphous ivacaftor, not the basic ivacaftor molecule.
- Claim 1 requires approximately 35 wt% of a solid dispersion containing approximately 80% ivacaftor, 19.5% HPMCAS, and 0.5% SLS.
- The remaining formulation requires mannitol, lactose, sucralose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate at specified approximate percentages.
- Claims 7 and 9 target approximately 50 mg and 75 mg doses delivered through approximately 26 and 39 mini-tablets.
- The “consisting of” language supports ingredient-based design-arounds.
- The amorphous-state limitation creates analytical and evidentiary issues in infringement disputes.
- The patent is materially narrower than the foundational ivacaftor compound patent.
- Its nominal expiration is approximately June 2029, subject to the official USPTO patent-term calculation.
- Generic applicants face ANDA and Paragraph IV issues, not biosimilar litigation.
- The strongest generic strategy is likely a different excipient system, solid state, dosage form, or mini-tablet architecture.
- Patent 8,883,206 must be assessed with the broader ivacaftor, combination-product, method-of-use, and Orange Book patent portfolio.
Frequently Asked Questions
Does Patent 8,883,206 cover all Kalydeco tablets?
No. It covers compositions meeting the specified amorphous ivacaftor solid-dispersion and excipient limitations. A Kalydeco product with a materially different formulation may fall outside the claims.
Can a generic use amorphous ivacaftor without infringing this patent?
Yes, potentially. Amorphous ivacaftor alone is not enough for infringement. The product must also satisfy the claimed HPMCAS/SLS dispersion and the required composition percentages, unless infringement is established under the doctrine of equivalents.
Does the patent cover ivacaftor in combination with lumacaftor or elexacaftor?
The supplied claims do not recite lumacaftor, tezacaftor, or elexacaftor. A combination product would need to be analyzed against this patent’s “consisting of” language and against separate combination-product patents.
Is a 2 mm mini-tablet required for every claim?
No. The 2 mm limitation appears only in claim 10. Claims 1 through 9 can cover compositions without that specific mini-tablet dimension, although claims 5 through 9 contain other mini-tablet requirements.
Can a manufacturer avoid the patent by changing only the number of mini-tablets?
Changing the number may avoid a claim directed to 26 or 39 mini-tablets, but it may not avoid claim 1 or claim 2. The complete claim dependency structure must be analyzed before reaching an infringement conclusion.
References
-
U.S. Patent No. 7,495,103. (2009). Quinolinone compounds as CFTR potentiators. U.S. Patent and Trademark Office.
-
U.S. Patent No. 8,883,206. (2014). Pharmaceutical compositions comprising ivacaftor. U.S. Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Kalydeco prescribing information. Vertex Pharmaceuticals Incorporated and FDA.
-
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources. USPTO.
